Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)
- Conditions
- Bacterial Vaginosis
- Interventions
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2019-07-22
- Lead Sponsor
- Starpharma Pty Ltd
- Target Recruit Count
- 586
- Registration Number
- NCT02237950
- Locations
- 🇺🇸
Florida Medical Center and Research Inc., Miami, Florida, United States
🇺🇸Lynn Institute of the Ozarks, Little Rock, Arkansas, United States
🇺🇸Women's Clinic of Lincoln, PC, Lincoln, Nebraska, United States
Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)
- Conditions
- Bacterial Vaginosis
- Interventions
- First Posted Date
- 2014-09-10
- Last Posted Date
- 2018-06-25
- Lead Sponsor
- Starpharma Pty Ltd
- Target Recruit Count
- 637
- Registration Number
- NCT02236156
- Locations
- 🇺🇸
Medical Center for Clinical Research, San Diego, California, United States
🇬🇧Sites Various, Plymouth, United Kingdom
🇺🇸Precision Trials, LLC, Phoenix, Arizona, United States
A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis
- Conditions
- Bacterial Vaginosis
- Interventions
- Drug: PlaceboDrug: 1% SPL7013 Gel
- First Posted Date
- 2012-04-16
- Last Posted Date
- 2019-07-17
- Lead Sponsor
- Starpharma Pty Ltd
- Target Recruit Count
- 251
- Registration Number
- NCT01577537
A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis
- Conditions
- Bacterial Vaginosis
- Interventions
- Drug: PlaceboDrug: 1% SPL7013 Gel
- First Posted Date
- 2012-04-13
- Last Posted Date
- 2019-07-17
- Lead Sponsor
- Starpharma Pty Ltd
- Target Recruit Count
- 250
- Registration Number
- NCT01577238
Dose-ranging Study of SPL7013 Gel for the Prevention of Bacterial Vaginosis (BV)
- Conditions
- Recurrent Bacterial Vaginosis (BV)
- Interventions
- Drug: 1% SPL7013 GelDrug: 3% SPL7013 GelDrug: placebo gel
- First Posted Date
- 2011-09-21
- Last Posted Date
- 2013-11-20
- Lead Sponsor
- Starpharma Pty Ltd
- Target Recruit Count
- 205
- Registration Number
- NCT01437722
Dose Ranging Study of SPL7013 Gel for Treatment of Bacterial Vaginosis (BV)
- Conditions
- Bacterial Vaginosis
- Interventions
- Drug: 3.0% SPL7013 GelDrug: 0.5% SPL7013 GelDrug: 1.0% SPL7013 GelOther: Placebo Gel
- First Posted Date
- 2010-09-14
- Last Posted Date
- 2019-06-06
- Lead Sponsor
- Starpharma Pty Ltd
- Target Recruit Count
- 132
- Registration Number
- NCT01201057
- Locations
- 🇺🇸
Precision Trials, Phoenix, Arizona, United States
🇺🇸Tidewater Clinical Research Inc, Virginia Beach, Virginia, United States
🇺🇸Clinical Research Center of Nevada, Las Vegas, Nevada, United States
Retention and Duration of Activity of SPL7013 (VivaGel®) After Vaginal Dosing.
- Conditions
- HSV-2 Genital HerpesHIV Infections
- Interventions
- Drug: 3% SPL7013 Gel (VivaGel)
- First Posted Date
- 2008-08-25
- Last Posted Date
- 2018-10-30
- Lead Sponsor
- Starpharma Pty Ltd
- Target Recruit Count
- 12
- Registration Number
- NCT00740584
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Australia
Safety and Acceptability of SPL7013 Gel (VivaGelâ„¢) in Sexually Active Women
- Conditions
- Healthy
- Interventions
- Drug: 3% SPL7013 Gel (VivaGel)Drug: Placebo GelDrug: HEC Placebo Gel
- First Posted Date
- 2007-03-05
- Last Posted Date
- 2010-06-24
- Lead Sponsor
- Starpharma Pty Ltd
- Target Recruit Count
- 61
- Registration Number
- NCT00442910
- Locations
- 🇺🇸
University of South Florida, Tampa, Florida, United States
🇺🇸Center for Family Planning Research, Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States
🇵🇷University of Puerto Rico, San Juan, Puerto Rico
SPL7013 Gel - Male Tolerance Study
- Conditions
- Human Immunodeficiency Virus (HIV)
- First Posted Date
- 2006-08-31
- Last Posted Date
- 2008-01-16
- Lead Sponsor
- Starpharma Pty Ltd
- Target Recruit Count
- 36
- Registration Number
- NCT00370357
- Locations
- 🇦🇺
Melbourne Sexual Health Centre, Carlton, Victoria, Australia